Barbara E Bierer

Barbara Emily Bierer, MD

Professor of Medicine (Pediatrics), HMS
Member, HMS Center for Bioethics

Barbara Bierer, MD is a Professor of Medicine (Pediatrics) at Harvard Medical School (HMS), and a hematologist/oncologist at the Brigham and Women's Hospital (BWH). She received her MD from HMS. She is the director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award, and the director of regulatory policy, SMART IRB. Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve the ethics, conduct, and regulatory environment for multi-site, multi-national clinical trials. She is a co-founder of COVID-19 Collaboration Platform, a platform for cooperation in research. In 2017, the MRCT Center launched the non-profit Vivli, a global clinical research data sharing platform. From 2003-2014, she served as Senior Vice President, Research, at BWH and was the institutional official for human subjects and animal research, for biosafety and for research integrity at the BWH. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. Dr. Bierer established and directed the Center for Faculty Development and Diversity at the BWH; for these efforts, she was the first recipient of the HMS Harold Amos Faculty Diversity Award.

Publications View
Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation.
Authors: Authors: Yeh WC, Li TK, Bierer BE, McKnight SL.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor.
Authors: Authors: Hutchcroft JE, Franklin DP, Tsai B, Harrison-Findik D, Varticovski L, Bierer BE.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells.
Authors: Authors: Fruman DA, Pai SY, Burakoff SJ, Bierer BE.
Mol Cell Biol
View full abstract on Pubmed
Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Authors: Authors: Bierer BE.
Proc Assoc Am Physicians
View full abstract on Pubmed
The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells.
Authors: Authors: Fruman DA, Bierer BE, Benes JE, Burakoff SJ, Austen KF, Katz HR.
J Immunol
View full abstract on Pubmed
Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation.
Authors: Authors: Liu SJ, Hahn WC, Bierer BE, Golan DE.
Biophys J
View full abstract on Pubmed
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
Authors: Authors: Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE.
Eur J Immunol
View full abstract on Pubmed
Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A.
Authors: Authors: Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, Antin JH, Bierer BE.
Blood
View full abstract on Pubmed
Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo.
Authors: Authors: Holländer GA, Fruman DA, Bierer BE, Burakoff SJ.
Transplantation
View full abstract on Pubmed
Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation.
Authors: Authors: Calvo V, Wood M, Gjertson C, Vik T, Bierer BE.
Eur J Immunol
View full abstract on Pubmed